GlassScriptPhysician profile
Lorenzo Gamez
NPI 1386823581
$19,195.97
in general payments reported to CMS, 2019-2025
29 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $4,700 · 2021: $836 · 2022: $4,479 · 2023: $5,115 · 2024: $670 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,708 · Travel and Lodging: $3,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.99 |
| Travel and Lodging | $3,412.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $6,343.65 | 2020-2023 | |
| Stryker Corporation | $4,059.33 | 2019-2025 | Inbone, Infinity, Prophecy |
| Polaris Technology Solutions LLC | $2,080.88 | 2022-2025 | |
| Tactile Systems Technology INC | $1,735.47 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Paragon 28, INC. | $1,282.21 | 2023-2025 | Portfolio, Ttc Nail, Mini Monster |
| Wright Medical Technology, INC. | $492.78 | 2019-2020 | |
| Bioventus LLC | $399.00 | 2019-2023 | Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $387.98 | 2023-2025 | Physio-Stim, Spinal-Stim |
| Djo, LLC | $370.46 | 2020-2025 | Cmf |
| Gotham Surgical Solutions & Devices, INC. | $365.40 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $296.73 | 2021-2023 | A.L.P.S. |
| Treace Medical Concepts, INC. | $287.30 | 2022-2025 | |
| Boston Scientific Corporation | $237.25 | 2024-2025 | Intracept |
| Horizon Therapeutics Plc | $178.44 | 2019-2022 | |
| Heron Therapeutics, INC. | $147.24 | 2022-2025 | Zynrelef |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $94.41 | 2020-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Sanara Medtech INC. | $58.28 | 2022 | |
| Osteoremedies, LLC | $48.69 | 2025 | Spectrum Gv, Biowash Surgical Irrigation, Osteoboost Select 5cc |
| Curonix LLC | $47.68 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Smith+Nephew, INC. | $46.42 | 2025 | Grafix, Oasis |
| Depuy Synthes Sales INC. | $44.70 | 2025 | Expedium Verse, Trialtis, Vivigen Mis Delivery System |
| Biocomposites INC | $41.56 | 2020-2025 | Stimulan |
| Checkpoint Surgical, INC | $38.47 | 2023 | Checkpoint Stimulators |
| Medartis INC. | $26.66 | 2020 | |
| Endo Pharmaceuticals INC. | $20.24 | 2019 | |
| Kerecis Limited | $19.11 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Ethicon US, LLC | $16.95 | 2025 | Vistaseal, Stratafix |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2023 | Seglentis |
| Mimedx Group, INC. | $13.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenzo Gamez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.